Loading
KCNH8 (Voltage-gated delayed rectifier potassium channel KCNH8) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Pore-forming (alpha) subunit of a voltage-gated delayed rectifier potassium channel that mediates outward-rectifying potassium currents. Elicits a slowly activating, non-inactivating and slowly deactivation outwards potassium current at depolarizating voltages from -30 mV to +50mV. Shows no obvious change in the activation rate from different holding potentials.
Open Targets scores its association with cancer at 0.56 (direct and indirect evidence; datatypes literature 0.12, animal model 0.45, genetic association 0.49, clinical 0.76).
In plain words · KCNH8 (Voltage-gated delayed rectifier potassium channel KCNH8) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
KCNH8 (Voltage-gated delayed rectifier potassium channel KCNH8) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Pore-forming (alpha) subunit of a voltage-gated delayed rectifier potassium channel that mediates outward-rectifying potassium currents.
No product in this corpus aims at KCNH8 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA group enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA KCNH8: RNA group enriched (brain 10 nTPM, pituitary gland 11 nTPM, retina 3 nTPM); blood lineage lineage enriched (B-cells 1 nTPM); high antibody staining in 2 normal tissues. Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 1 specific cancer type at or above 0.5 (Lambert-Eaton myasthenic syndrome). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas KCNH8 tissue; Open Targets ENSG00000183960 associations
First described 2002. Earliest sequence paper UniProt cites for the protein: Baxter D.F. et al, J. Biomol. Screen, 2002, "A novel membrane potential-sensitive fluorescent dye improves cell-based assays for ion channels". Source.
Sources: HGNC HGNC:18864 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q96L42 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000183960 (association with cancer (MONDO_0004992) 0.56; (GraphQL API, CC0))
Pore-forming (alpha) subunit of a voltage-gated delayed rectifier potassium channel that mediates outward-rectifying potassium currents. Elicits a slowly activating, non-inactivating and slowly deactivation outwards potassium current at depolarizating voltages from -30 mV to +50mV. Shows no obvious change in the activation rate from different holding potentials. Activation is strongly dependent on the pH of the external solution. Location: Membrane (UniProt). Locus 3p24.3 (HGNC).
RNA: group enriched (brain 10 nTPM, pituitary gland 11 nTPM, retina 3 nTPM), detected in some normal tissues. Blood: lineage enriched (B-cells 1 nTPM).
Medium: Caudate, Cerebral cortex, Hippocampus, Kidney, Stomach.
No cancer stained high; medium in pancreatic cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"KCNH8" OR ABSTRACT:"KCNH8" OR TITLE:"potassium voltage-gated channel subfamily H member 8" OR ABSTRACT:"potassium voltage-gated channel subfamily H member 8" OR TITLE:"Voltage-gated delayed rectifier potassium channel KCNH8" OR ABSTRACT:"Voltage-gated delayed rectifier potassium channel KCNH8" OR TITLE:"Kv12.1" OR ABSTRACT:"Kv12.1" OR TITLE:"elk3" OR ABSTRACT:"elk3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KCNH8, not a curated reading list.